CStone Pharmaceuticals (2616.HK)
HKD 2.39
(-6.64%)
HKD 2.39
(-6.64%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 463.84 Million | 481.36 Million | 243.71 Million | 1.03 Billion | - | 12.55 Million |
| Cost of Revenue | 159.54 Million | 202.98 Million | 106.83 Million | 241.42 Million | - | - |
| Gross Profit | 304.29 Million | 278.37 Million | 136.88 Million | 797.41 Million | - | 12.55 Million |
| Operating Expenses | 304.29 Million | 1.18 Billion | 1.93 Billion | 1.86 Billion | 1.73 Billion | 1.05 Billion |
| Selling, General and Administrative Expenses | 248.06 Million | 390.47 Million | 472.99 Million | 228.88 Million | 86.22 Million | 81.38 Million |
| Research and Development Expenses | 527.79 Million | 614.16 Million | 1.3 Billion | 1.4 Billion | 1.39 Billion | 850.19 Million |
| Other Expenses | - | 177.24 Million | 152.42 Million | 228.26 Million | 256.21 Million | 127.52 Million |
| Cost and Expenses | 1.04 Billion | 1.38 Billion | 2.03 Billion | 2.1 Billion | 1.73 Billion | 1.05 Billion |
| Operating Income | -534.6 Million | -832.27 Million | -1.85 Billion | -1.22 Billion | -1.56 Billion | -1.05 Billion |
| Interest Expense | 11.81 Million | 8.47 Million | 2.24 Million | 1.32 Million | 303 Thousand | - |
| Income Tax Expense | - | 61.92 Million | 67.34 Million | -1.09 Million | 748.39 Million | -734.03 Million |
| Earnings before Tax | -367.23 Million | -902.67 Million | -1.92 Billion | -1.22 Billion | -2.3 Billion | -1.79 Billion |
| Net Income | -367.23 Million | -964.6 Million | -1.98 Billion | -1.21 Billion | -3.05 Billion | -1.74 Billion |
| Earnings Per Share Basic | -0.29 | -0.82 | -1.71 | -1.17 | -3.53 | -1.79 |
| Earnings Per Share Diluted | -0.29 | -0.82 | -1.71 | -1.17 | -3.53 | -1.77 |
| Weighted Average Shares Outstanding | 1.26 Billion | 1.17 Billion | 1.16 Billion | 1.04 Billion | 865.58 Million | 973.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.26 Billion | 1.17 Billion | 1.16 Billion | 1.04 Billion | 866.72 Million | 984.05 Million |
| Gross Margin | 0.66 | 0.58 | 0.56 | 0.77 | - | 1.00 |
| EBIT Margin | -0.64 | -1.64 | -7.51 | -1.16 | - | -73.02 |
| Profit Margin | -0.79 | -2.00 | -8.15 | -1.17 | - | -139.07 |
| EBITDA | -297.22 Million | -849.66 Million | -1.89 Billion | -1.2 Billion | -1.73 Billion | -1.02 Billion |
| Earnings Before Tax Margin | -1.15 | -1.73 | -7.60 | -1.18 | - | -84.39 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 127.08 Million | 127.08 Million | 101.18 Million | 463.84 Million | 101.18 Million | 130.73 Million |
| Cost of Revenue | 41.06 Million | 41.06 Million | 25.75 Million | 159.54 Million | 25.75 Million | 54.01 Million |
| Gross Profit | 86.01 Million | 86.01 Million | 75.42 Million | 304.29 Million | 75.42 Million | 76.71 Million |
| Operating Expenses | 87.84 Million | 87.84 Million | 251.22 Million | 884.14 Million | 156.21 Million | 186.08 Million |
| Selling, General and Administrative Expenses | 54.72 Million | 54.72 Million | 80.71 Million | - | 80.71 Million | 110.31 Million |
| Research and Development Expenses | 33.12 Million | 33.12 Million | 170.51 Million | - | 170.51 Million | 93.38 Million |
| Other Expenses | - | - | - | -8000.00 | - | - |
| Cost and Expenses | 128.91 Million | 128.91 Million | 276.98 Million | 1.04 Billion | 181.96 Million | 240.1 Million |
| Operating Income | -1.83 Million | -1.83 Million | -175.8 Million | -534.6 Million | -175.8 Million | -126.98 Million |
| Interest Expense | - | - | - | 11.81 Million | - | 6.64 Million |
| Income Tax Expense | - | - | - | 58.02 Million | - | 2.00 |
| Earnings before Tax | 7.84 Million | 7.84 Million | -79 Million | -367.23 Million | -79 Million | -104.61 Million |
| Net Income | 7.84 Million | 7.84 Million | -79 Million | -367.23 Million | -79 Million | -104.61 Million |
| Earnings Per Share Basic | 0.01 | 0.01 | -0.06 | - | -0.06 | -0.08 |
| Earnings Per Share Diluted | 0.01 | 0.01 | -0.06 | - | -0.06 | -0.08 |
| Weighted Average Shares Outstanding | 1.56 Billion | 1.56 Billion | 1.27 Billion | 1.26 Billion | 1.27 Billion | 1.23 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.27 Billion | 1.27 Billion | 1.27 Billion | 1.26 Billion | 1.27 Billion | 1.25 Billion |
| Gross Margin | 0.68 | 0.68 | 0.75 | 0.66 | 0.75 | 0.59 |
| EBIT Margin | 0.01 | 0.01 | -1.69 | - | -1.69 | -0.93 |
| Profit Margin | 0.06 | 0.06 | -0.78 | -0.79 | -0.78 | -0.80 |
| EBITDA | 1.61 Million | 1.61 Million | -171.19 Million | - | -171.19 Million | -122.13 Million |
| Earnings Before Tax Margin | -0.01 | -0.01 | -1.74 | -1.15 | -1.74 | -0.97 |
4931
CKPT
CASY
ITERA
PMT-PC
IAM